摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

PtI2(2,2´-dipyridylamine) | 125859-59-8

中文名称
——
中文别名
——
英文名称
PtI2(2,2´-dipyridylamine)
英文别名
[Pt(2,2'-dipyridylamine)I2];[platinum(II)I2(2,2'-dipyridylamine)];platinum(2+);N-pyridin-2-ylpyridin-2-amine;diiodide
PtI<sub>2</sub>(2,2´-dipyridylamine)化学式
CAS
125859-59-8
化学式
C10H9I2N3Pt
mdl
——
分子量
620.091
InChiKey
ZISACWWFPBWWPR-UHFFFAOYSA-L
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -3.77
  • 重原子数:
    16
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    37.8
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    PtI2(2,2´-dipyridylamine) 在 sodium hydroxide 作用下, 以 甲醇乙腈 为溶剂, 反应 552.0h, 生成 bis[N-(2-pyridinyl)-2-pyridinaminate]platinum(II) triflate
    参考文献:
    名称:
    Platinum complexes bearing 2,2′-dipyridylamine ligand
    摘要:
    在乙腈中用三酸银取代[PtI2(dpa)](1)复合物(dpa 是 2,2′-二吡啶基胺)中的碘配体,得到了[Pt(dpa)(MeCN)2](SO3CF3)2 (2)。在甲醇(X = NO3)或乙腈(X = SO3CF3)中,在银盐 AgX 的存在下,用 2,2′-二吡啶胺处理[PtI2(dpa)](1),合成了均质配合物[Pt(dpa)2](X)2 (3-(X)2)。复合物[3](SO3CF3)2 的去质子化得到同质复合物[Pt(dpa-H)2](4)的方法有两种,例如在甲醇中用 2 等量的 NaOH 处理[3](SO3CF3)2,或在甲醇中向[3](SO3CF3)2 的悬浮液中加入过量 Et3N。化合物 1-4 的结构是通过元素分析、高分辨率电喷雾电离质谱、红外光谱和核磁共振光谱确定的;复合物 [2](SO3CF3)2、[3](NO3)2-H2O、[3](SO3CF3)2-2H2O 和 4 的晶体结构是通过单晶 X 射线衍射确定的。
    DOI:
    10.1007/s11172-012-0115-5
  • 作为产物:
    描述:
    potassium tetrachloroplatinate(II)2,2'-二吡啶胺 在 potassium iodide 作用下, 以 为溶剂, 生成 PtI2(2,2´-dipyridylamine)
    参考文献:
    名称:
    Joshi; Gijare, Journal of the Indian Chemical Society, 1989, vol. 66, # 7, p. 474 - 475
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Cisplatin analogues with 2,2′-dipyridylamine ligands and their reactions with DNA model nucleobases
    作者:Michael J Rauterkus、Sarah Fakih、Christian Mock、Ina Puscasu、Bernt Krebs
    DOI:10.1016/s0020-1693(02)01540-2
    日期:2003.7
    Six novel platinum(II) and palladium(II) complexes with */ cisplatin */ analogous configuration were prepared and could be obtained as single crystals for X-ray structure analyses. The ligand system based on 2,2?-dipyridylamine was extended stepwise by adding alkyl chains to the bridging nitrogen atom, starting from pure 2,2?-dipyridylamine to (2,2?-dipyridyl)-n -butylamine. In the case of [Pt(dpa)Cl2]
    制备了六种具有* /顺铂* /类似构型的新型(II)和(II)配合物,它们可以作为单晶获得,用于X射线结构分析。通过将烷基链加到桥接的氮原子上,逐步扩展基于2,2′-二吡啶基胺的配体体系,从纯的2,2′-二吡啶基胺到(2,2′-二吡啶基)-正丁胺开始。在[Pt(dpa)Cl2]和[Pt(dpma)Cl2]的情况下,研究了解复合物分别与模型核碱基1-甲基胸腺嘧啶和1-甲基尿嘧啶的反应。所得的Pt(II)/ dpa /甲基胸苷和Pt(II)/ dpa / dpma /甲基尿嘧啶络合物也可以通过X射线衍射进行表征。化合物与模型核碱基形成双核络合物,通过其N3和O4供体原子充当二级桥连配体。双(m -1-甲基胸腺嘧啶-N3 -O4)双[2,2?二吡啶(II)]六氟磷酸硝酸高氯酸盐二水合物(10)(三斜晶系,空间群P / 1)头对头包含模型核碱基。取向,而双(m -1-甲基尿嘧啶-N3-O4)[2
  • Facile base-free addition of methanol to PtII-activated nitriles. X-ray structure of a platinum(II) complex bearing unsymmetrical N-bound urea
    作者:Qian Wang、Pavel V. Gushchin、Nadezhda A. Bokach、Matti Haukka、Vadim Yu. Kukushkin
    DOI:10.1016/j.ica.2011.11.003
    日期:2012.3
    The nitrile complex [Pt(dpa)(NCNMe2)(2)](SO3CF3)(2)center dot 2H(2)O (2 center dot 2H(2)O) was prepared by treatment of [PtI2(dpa)] with AgSO3CF3 in dimethylcyanamide. When the abstraction of the iodide ligand was performed in a RCN-MeOH mixture, the imino ester complexes [Pt(dpa)NH=C(OMe)R}(2)](SO3CF3)(2) (R = Me 3, NMe2 4) were formed and these species were isolated in 76% and 70% yields, respectively. Complexes 3 and 4 were also generated when [Pt(dpa)(NCMe)(2)](SO3CF3)(2) (1) and 2 center dot 2H(2)O, correspondingly, were dissolved in MeOH. The formulation of complexes was supported by agreeable ESI+-MS, IR, H-1 and C-13H-1} NMR spectroscopies; the structure of 4 was determined by the single-crystal X-ray diffraction. (C) 2011 Elsevier B. V. All rights reserved.
  • Phosphorescent Pt <sup>II</sup> Systems Featuring Both 2,2′‐Dipyridylamine and 1,3,5‐Triazapentadiene Ligands
    作者:Ivan I. Eliseev、Pavel V. Gushchin、Yi‐An Chen、Pi‐Tai Chou、Matti Haukka、Galina L. Starova、Vadim Yu. Kukushkin
    DOI:10.1002/ejic.201402364
    日期:2014.9
    AbstractThe treatment of cis‐[Pt(dpa)(RCN)2][SO3CF3]2 dpa = 2,2′‐dipyridylamine, R = Me, Et, CH2Ph, Ph; [2ad](OTf)2} (OTf = SO3CF3) with 2 equiv. of N,N′‐diphenylguanidine [NH=C(NHPh)2] in CH2Cl2 solutions at room temp. for 16 h gives [Pt(dpa)NH=C(R)NC(NHPh)=NPh}][SO3CF3] [3a,b,d](OTf)} as the addition products and [Pt(dpa)NH=C(R)NHC(R)=NH}][SO3CF3]2 [4a,b](OTf)2} as the tailoring products. The formulation of complexes [3a,b,d](OTf) and [4a,b](OTf)2 was supported by satisfactory C, H, and N elemental analyses and agreeable high‐resolution ESI‐MS, IR, and 1H (including 1H–1H COSY experiments) and 13C1H} NMR data. The structures of all of the platinum species were determined by single‐crystal X‐ray diffraction. The resultant complexes are nonemissive in solution, mainly because of the interaction between the empty d orbital in a square‐planar configuration and solvent molecules. However, in the solid state, complexes [3a,b,d](OTf) exhibit strong phosphorescence with quantum yields (peak wavelength) of 0.23 (490 nm), 0.27 (483 nm), and 0.20 (532 nm), respectively.
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (双(2,2,2-三氯乙基)) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-氨氯地平-d4 (S)-8-氟苯并二氢吡喃-4-胺 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯 (R,S)-可替宁N-氧化物-甲基-d3 (R,S)-六氢-3H-1,2,3-苯并噻唑-2,2-二氧化物-3-羧酸叔丁酯 (R)-(+)-5'-苄氧基卡维地洛 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-卡洛芬 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (R)-4-异丙基-2-恶唑烷硫酮 (R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) (E)-2-氰基-3-(5-(2-辛基-7-(4-(对甲苯基)-1,2,3,3a,4,8b-六氢环戊[b]吲哚-7-基)-2H-苯并[d][1,2,3]三唑-4-基)噻吩-2-基)丙烯酸 (E)-2-氰基-3-[5-(2,5-二氯苯基)呋喃-2-基]-N-喹啉-8-基丙-2-烯酰胺 (8α,9S)-(+)-9-氨基-七氢呋喃-6''-醇,值90% (6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 (6-羟基嘧啶-4-基)乙酸 (6,7-二甲氧基-4-(3,4,5-三甲氧基苯基)喹啉) (6,6-二甲基-3-(甲硫基)-1,6-二氢-1,2,4-三嗪-5(2H)-硫酮) (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-(4-乙氧基-3-甲基苄基)-1,3-苯并二恶茂) (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (5-氨基-1,3,4-噻二唑-2-基)甲醇 (4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] (4-(4-氯苯基)硫代)-10-甲基-7H-benzimidazo(2,1-A)奔驰(德)isoquinolin-7一 (4-苄基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (4-己基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4,5-二甲氧基-1,2,3,6-四氢哒嗪)